From May 15 through May 18, the American Urological Association (AUA) is hosting its 2026 annual conference in Washington, DC. For four days, the 2026 AUA Annual Meeting will explore the latest advances in urologic medicine presented by leaders of the global urologic community.

Today’s preview highlights currently scheduled sessions focusing on bladder cancer. Dates and times are current as of Monday, April 13, 2026. Some session descriptions have been edited for clarity or brevity. For a complete look at the 2026 AUA meeting schedule, view the full program.

Bladder Cancer Sessions at the 2026 AUA Annual Meeting

Friday, May 15

  • Bladder Cancer: Non-Invasive I
    • 7:00 AM – 9:00 AM
    • Description: This poster session includes the following: Development of a Non-Muscle Invasive Bladder Cancer (NMIBC) Genomic Score (NGS) that Outperforms Clinical Parameters to Predict Early BCG Failure, Cost-Effectiveness Analysis of Sasanlimab plus BCG for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): Analysis from CREST, and more.
  • Upper Tract Urothelial Carcinoma Tumor Board
    • 10:00 AM – 12:00 PM
    • Description: This is a tumor board style course, with case presentations ranging from low-risk disease managed conservatively to high-risk and metastatic disease requiring multidisciplinary management, that will highlight key issues in the care of patients with UTUC and incorporate the AUA UTUC guidelines. A multidisciplinary faculty panel will discuss their recommendations and their rationale.
  • Bladder Cancer: Non-Invasive II
    • 3:30 PM – 5:30 PM
    • Description: This poster session includes the following: BCG-Rechallenge After Treatment Failure: Long-Term Outcomes from a Multi-Institutional Cohort, Real-World Outcomes of Bladder-Sparing Strategies for BCG-Unresponsinve Non-Muscle-Invasive Bladder Cancer: A Multicenter Study, and more.
  • Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them
    • 4:00 PM – 6:00 PM
    • Description: The course will highlight recent updates to AUA, European Association of Urology and National Comprehensive Cancer Network Guidelines in the rapidly evolving field of bladder cancer before working through challenging but common case scenarios that will outline important changes as well as concepts essential in providing evidence-based care.
Saturday, May 16
  • Bladder Cancer: Upper Tract Transitional Cell Carcinoma I
    • 7:00 AM – 9:00 AM
    • Description: This session includes the following: Long-Term Follow-Up Results of aMVAC Arm of ECOG-ACRIN EA8141: a Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High-Grade Upper Tract Urothelial Carcinoma, and more.
  • Bladder Cancer: Non-Invasive III
    • 7:00 AM – 9:00 AM
    • Description: This session includes the following: Extended Clinical Outcomes of Neoadjuvant Intravesical Mitomycin-c Therapy Administered Immediately Prior to Transurethral Resection of Bladder Tumor in Non-Muscle Invasive Bladder Cancer: Over 3 Years of Follow-up Data from a Randomized Phase II, and more.
  • Bladder Cancer: Epidemiology & Evaluation I
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Predictors of Adherence to Intravesical Bacillus Calmette-Guerin (BCG) Induction Schedules for the Treatment of Early Bladder Cancer Among U.S. Medicare Beneficiaries from 2004 to 2019, Artificial Intelligence Diagnostics for Bladder Tumor Identification and Grade Prediction Depend on Narrow Band Imaging Cystoscopy, and more.
  • Bladder Cancer: Invasive I
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Comparable Prognostic Utility of Circulating Tumor DNA in Patients with Pure and Variant Histology Bladder Cancer Undergoing Radical Cystectomy, Integrative Clinical and Molecular Characterization of Metastasis and Resistance to Antibody-Drug Conjugates in Sarcomatoid Variant Bladder Cancer, and more.
  • Management of Non-Muscle Invasive Bladder Cancer: Practical Management of Common Problems in the Everchanging Treatment Landscape
    • 10:00 AM – 12:00 PM
    • Description: This course will focus on specific topics discussed in the recent/amended AUA practice guidelines for non-muscle-invasive bladder cancer (NMIBC) and detail strategies to manage common clinical predicaments involved in the management of these tumors. The course will include short didactic lectures by each of the faculty but will focus predominantly on case presentations highlighting common and often perplexing topics in NMIBC.
  • Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team
    • 10:30 AM – 12:00 PM
    • Description: New for 2026, Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team will offer education and updates to the urology care team on the complex management of bladder cancer patients and the latest advancements in NMIBC.
  • Bladder Cancer: Invasive II
    • 1:00 PM – 3:00 PM
    • Description: This session includes the following: The Optimal Extent of Lymph Node Dissection in Patients with Bladder Squamous Cell Carcinoma: A Population-Based Study, The Use of ctDNA From Paired Blood and Urine to Predict Recurrence After Extirpative Surgery for the Treatment of Urothelial Carcinoma, and more.
  • Bladder Cancer: Epidemiology & Evaluation II
    • 1:00 PM – 3:00 PM
    • Description: This session includes the following: Preoperative Circulating Tumor DNA Identifies Biologically Aggressive Disease Beyond Nodal Status in Bladder Cancer, Bladder Cancer Risk with Pioglitazone Use: Implications for Bladder Cancer Monitoring and Treatment, Detection of Bladder Cancer in Patients with Gross Hematuria using Oncuria-Detect, a Urine-Based Multiplex Immunoassay, and more.
  • Bladder Cancer: Basic Research & Pathophysiology I
    • 3:30 PM – 5:30 PM
    • Description: This session includes the following: Investigation of Carcinogenic Effects of Polystyrene Microplastic on Human Bladder Cancer Cells, A Universal Molecular Map of Bladder Cancer: From Cell Lines in Vitro to Tumors and Back Using Co-Regulatory Networks, and More.
  • Bladder Cancer: Invasive III
    • 3:30 PM – 5:30 PM
    • Description: This session includes the following: Examining the Impact of TGF-b Activity on Fibroblast Infiltration and Immune Exclusion in Muscle-Invasive Bladder Cancer, AI-Based Analysis of Perivascular Regions from H&E Predicts Survival in Muscle-Invasive Bladder Cancer, and more.
Sunday, May 18
  • Bladder Cancer: Non-invasive IV
    • 7:00 AM – 9:00 AM
    • Description: This session includes the following: Oncological Benefits of a Single Immediate Instillation of Chemotherapy in Patients with High-risk Non-Muscle-Invasive Bladder Cancer Who Receive Adjuvant Induction Bacillus Calmette-Guérin Therapy, Defining Unique Molecular Signatures of Young-Onset Non–Muscle-Invasive Bladder Cancer, and more.
  • Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multidisciplinary Case-Based Approach to Management
    • 7:30 AM – 9:30 AM
    • Description: This instructional course is a multidisciplinary case-based approach to review options for muscle invasive bladder cancer, with an educational focus on trimodality therapy (TMT) as compared with radical cystectomy. [The presenters] will review a diverse set of real clinical cases in a tumor board style discussion with a multidisciplinary faculty including urology, radiation oncology, and medical oncology.
  • Clinical Trials in Progress: Bladder Cancer
    • 9:00 AM – 11:00 AM
    • Description: This session includes the following: Safety and Efficacy of Bel-sar (AU-011), a Virus-Like Drug Conjugate, in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC), A Phase II Study of Intravesical HM-001 in Patients with Non–Muscle-Invasive Bladder Cancer Following Safe Completion of a Phase I Trial, and more.
  • Bladder Cancer: Upper Tract Transitional Cell Carcinoma II
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Assessing Upper Tract Urothelial Carcinoma Metabolism with Intraoperative Isotope Tracing, Evaluation of the Impact of Positive Ureteral Margin on Upper Tract Recurrence Following Radical Cystectomy for Bladder Cancer, Hypoalbuminemia as an Independent Prognostic Factor in Clinically Node-Positive Upper Tract Urothelial Carcinoma Without Distant Metastasis, and more.
  • Bladder Cancer: Invasive IV
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Prognostic Value of Perioperative ctDNA Dynamics in Patients Undergoing Radical Cystectomy for Bladder Cancer, Extended Versus Standard Lymphadenectomy in Muscle-Invasive Bladder Cancer: Real-World Data Confirming Trial-Based Evidence and the Prognostic Role of Pathological Staging, and more.
  • AUA-IBCG Bladder Cancer Forum
    • 2:00 PM – 5:00 PM
    • Description: This session includes the following: Debate 1: TMT for MIBC: Radiation, Responsibility – Who Manages the Fallout, and How?, Update from the International Bladder Cancer Group (IBCG), Debate 5: In 2026, MRI with VIRADS is Mandatory for the Staging and therapeutic planning for Bladder Cancer, and more.

Monday, May 18

  • Bladder Cancer: Basic Research & Pathophysiology II
    • 7:00 AM – 9:00 AM
    • Description: This session includes the following: Prospective Analytical Study Using Real-Time Artificial Intelligence (AI) to Optimize the Diagnostic of Bladder Tumor Detection, Discovery of a Rare Mesenchymal-Like Urothelial Cell Population Resembling the Phenotype of Sarcomatoid Component of MB49 Bladder Cancer Model, and more.
  • Bladder Cancer: Non-invasive V
    • 7:00 AM – 9:00 AM
    • Description: This session includes the following: Intravesical Versus Intravenous Therapy of Camrelizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer: Results from a Randomized Parallel-Cohort Phase I–II Study, Treatment with UGN-102 in Patients with Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-month Duration of Response Data from the Phase 3 ENVISION Trial, and more.
  • Difficult Cases in High-Risk Bladder Cancer and Evidence-Based Approach
    • 7:30 AM – 9:30 AM
    • Description: This session covers real world cases of challenging and evolving situations in the management of bladder cancer. This field is changing very fast and these cases illustrate the changes and are based on the best available evidence or guidelines.
  • Bladder Cancer: Invasive V
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Implications of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score as a Predictor of Neoadjuvant Chemotherapy Response in Patients with Muscle-Invasive Bladder Cancer Planning to Undergo Radical Cystectomy, Organ-Specific Efficacy of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis, and more.
  • Bladder & Urothelial Upper Tract Oncology
    • 9:30 AM – 11:30 AM
    • Description: This session includes the following: Video-based en bloc resection of upper tract urothelial carcinoma using a flexible and navigable suction ureteral access sheath and thulium fiber laser with stereotactic ablative radiotherapy: Feasibility and early outcomes, and more.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.